

## Anti-VEGF (Bevacizumab), Humanized Antibody

|                            |   |
|----------------------------|---|
| <b>ALTERNATE NAMES:</b>    | ABP 215, ABP-215, R-435, rhuMAb-VEGF  |
| <b>CATALOG NO. :</b>       | A1045-100   |
| <b>AMOUNT:</b>             | 100 µg  |
| <b>IMMUNOGEN:</b>          | Recombinant human VEGF  |
| <b>HOST/ISOTYPE:</b>       | Human IgG1  |
| <b>CLONALITY:</b>          | Monoclonal  |
| <b>FORM:</b>               | Liquid  |
| <b>FORMULATION:</b>        | 100 µg (1 mg/ml) of purified monoclonal anti-VEGF human IgG1 antibody in phosphate buffered saline, pH 7.4.                             |
| <b>PURIFICATION:</b>       | Selected human IgG1 was expressed in a human cell line. IgG was purified from CHO cell culture supernatant by protein A chromatography. |
| <b>SPECIES REACTIVITY:</b> | Human   |
| <b>STORAGE CONDITIONS:</b> | For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.  |

**DESCRIPTION:** Bevacizumab is a recombinant humanized monoclonal IgG1 antibody. Bevacizumab, targets the cell surface protein called vascular endothelial growth factor (VEGF) results in suppression of tumor growth. VEGF plays an essential role in developmental angiogenesis and is also important for reproductive and bone angiogenesis. Avastin is used to treat various cancers like metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma and metastatic renal cell carcinoma.

**APPLICATION:** Neutralization: 0.1-5 µg/ml, ELISA: 1 µg/ml

**Note:** This information is only intended as a guide. The optimal dilutions must be determined by the user.

### RELATED PRODUCTS:

#### ELISA Kits:

- VEGF (human) ELISA Kit (Cat. No. K5363-100)
- VEGF (mouse) ELISA Kit (Cat. No. K5364-100)
- VEGF (rat) ELISA Kit (Cat. No. K5365-100)

#### Recombinant proteins:

- VEGF-B, human recombinant (Cat. No. 4642-100)
- VEGF-C, human recombinant (Cat. No. 4633-50)
- VEGF-C, murine recombinant (Cat. No. 4634-10)
- VEGF-C, rat recombinant (Cat. No. 4635-10)
- VEGF-D, human recombinant (Cat. No. 4643-10)
- VEGF120, murine recombinant (Cat. No. 4964-10)
- VEGF121, human recombinant (Cat. No. 4963-10)
- VEGF165, human recombinant (Cat. No. 4363-10)
- VEGF165, murine recombinant (Cat. No. 4364-10)
- VEGF165, rat recombinant (Cat. No. 4365-10)
- VEGFR2, human recombinant (Cat. No. 4952-10)
- EG-VEGF, human recombinant (Cat. No. 4571-10)
- Human CellExp™ VEGF 121, Human Recombinant (Cat. No. 6484-10)
- Human CellExp™ VEGF 165, Human Recombinant (Cat. No. 6485-10)
- Human CellExp™ VEGF R1 /Flt-1, human recombinant (Cat. No. 7230-10)
- Human CellExp™ VEGF-B, human recombinant (Cat.No.7399-20)
- Human CellExp™ VEGF-C, human recombinant (Cat.No.7231-10)
- Human CellExp™ VEGF120, mouse recombinant ((Cat.No.7424-10)
- Human CellExp™ VEGF164, mouse recombinant (Cat.No.7425-10)
- Human CellExp™ VEGFR2/Flk-1/KDR, human recombinant (Cat.No.7399-20)

#### Antibodies

- Anti-HER2 (Trastuzumab), humanized antibody (Cat. No. A1046-100)
- Anti-EGFR (Cetuximab), chimeric antibody (Cat. No. A1047-100)
- Anti-TNF-α (Adalimumab), humanized antibody (Cat. No. A1048-100)
- Anti-CD20 (Rituximab), chimeric antibody (Cat. No. A1049-100)
- Anti-EGFR (Panitumumab), humanized antibody (Cat. No. A1050-100)
- VEGF Antibody (Cat. No. 5363-100BFAF)
- VEGF-B Antibody (Cat. No. 5641-100)
- VEGF-C Antibody (Cat. No. 5633-100)
- VEGF-D Antibody (Cat. No. 5643-100)

**FOR RESEARCH USE ONLY! Not to be used on humans.**